SEC Form 4 · accession 0001209191-18-013505
ANTARES PHARMA, INC. · ATRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert F Apple
Officer — President & CEO · Director
Period of report
Feb 22, 2018
Accepted (ET)
Feb 26, 2018 · 5:46 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001016169
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 22, 2018 | A | 113,835 | $0.00 | A | 1,289,472 | D | |
| Common Stock | Feb 22, 2018 | F | 37,001 | $2.20 | D | 1,252,471 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On May 28, 2015, Mr. Apple was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three year performance period ended December 31, 2017. The number of shares acquired represent the total number of shares earned upon achievement of two performance goals, the achievement of which was certified on February 22, 2018. The shares disposed represents the number of shares withheld to settle tax liability in connection with the vesting of the performance stock unit award.